Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03397706 · OUTCOME

Half-life of VRx-3996

Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies · Source last updated 2025-03-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
hours
Interval / dispersion
Standard Deviation
Time frame
Phase 1b: Cycle 1 Day 1 and Phase 2: multiple doses through Cycle 2 Day 1

What was measured

PK assessment of VRx-3996 pre-dose and at hours 0.5, 1, 2, 4, and 6 post-dose on C1D1 and C2D1

Analysis population: The PK Analysis Set was used for all PK analyses and included all patients in the intent-to-treat population (defined as all enrolled patients) who had at least one postdose measurable PK concentration. The PK Analysis Set will be used for individual plasma concentration listings and summaries of plasma concentrations.

Groups in this outcome

Phase 1b Dose Escalation Cohort 2a

VRx-3996: 5 mg BID valganciclovir: 450 mg BID

Phase 1b Dose Escalation Cohorts 1, 2b and 2c

VRx-3996: 10 mg QD or BID valganciclovir: 450 mg QD or BID or 900 mg QD or BID

Phase 1b Dose Escalation Cohort 3

VRx-3996: 20 mg QD on Days 1 to 4/week valganciclovir: 900 mg QD

Phase 2 RP2D - Capsule

VRx-3996: 20 mg QD on Days 1 to 4/week valganciclovir: 900 mg QD

Phase 2 RP2D - Tablet

VRx-3996: 20 mg QD on Days 1 to 4/week valganciclovir: 900 mg QD

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Phase 1b Dose Escalation Cohort 2a5
Phase 1b Dose Escalation Cohorts 1, 2b and 2c15
Phase 1b Dose Escalation Cohort 35
Phase 2 RP2D - Capsule30
Phase 2 RP2D - Tablet9

Reported measurements

Single-dose

Analysis denominator · Participants

GroupSource count
Phase 1b Dose Escalation Cohort 2a5
Phase 1b Dose Escalation Cohorts 1, 2b and 2c13
Phase 1b Dose Escalation Cohort 30
Phase 2 RP2D - Capsule16
Phase 2 RP2D - Tablet8
Values in hours · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Phase 1b Dose Escalation Cohort 2a1.890.252Not reportedNot reportedNot reported
Phase 1b Dose Escalation Cohorts 1, 2b and 2c1.440.466Not reportedNot reportedNot reported
Phase 2 RP2D - Capsule1.460.589Not reportedNot reportedNot reported
Phase 2 RP2D - Tablet1.430.287Not reportedNot reportedNot reported
Multiple-dose

Analysis denominator · Participants

GroupSource count
Phase 1b Dose Escalation Cohort 2a0
Phase 1b Dose Escalation Cohorts 1, 2b and 2c0
Phase 1b Dose Escalation Cohort 30
Phase 2 RP2D - Capsule5
Phase 2 RP2D - Tablet6
Values in hours · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Phase 2 RP2D - Capsule1.100.181Not reportedNot reportedNot reported
Phase 2 RP2D - Tablet1.871.33Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.252
        value
        1.89
      2. group Id
        OG001
        spread
        0.466
        value
        1.44
      3. group Id
        OG003
        spread
        0.589
        value
        1.46
      4. group Id
        OG004
        spread
        0.287
        value
        1.43
    denoms
    1. counts
      1. group Id
        OG000
        value
        5
      2. group Id
        OG001
        value
        13
      3. group Id
        OG002
        value
        0
      4. group Id
        OG003
        value
        16
      5. group Id
        OG004
        value
        8
      units
      Participants
    title
    Single-dose
  2. categories
    1. measurements
      1. group Id
        OG003
        spread
        0.181
        value
        1.10
      2. group Id
        OG004
        spread
        1.33
        value
        1.87
    denoms
    1. counts
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        0
      3. group Id
        OG002
        value
        0
      4. group Id
        OG003
        value
        5
      5. group Id
        OG004
        value
        6
      units
      Participants
    title
    Multiple-dose
denoms
  1. counts
    1. group Id
      OG000
      value
      5
    2. group Id
      OG001
      value
      15
    3. group Id
      OG002
      value
      5
    4. group Id
      OG003
      value
      30
    5. group Id
      OG004
      value
      9
    units
    Participants
description
PK assessment of VRx-3996 pre-dose and at hours 0.5, 1, 2, 4, and 6 post-dose on C1D1 and C2D1
dispersion Type
Standard Deviation
groups
  1. description
    VRx-3996: 5 mg BID valganciclovir: 450 mg BID
    id
    OG000
    title
    Phase 1b Dose Escalation Cohort 2a
  2. description
    VRx-3996: 10 mg QD or BID valganciclovir: 450 mg QD or BID or 900 mg QD or BID
    id
    OG001
    title
    Phase 1b Dose Escalation Cohorts 1, 2b and 2c
  3. description
    VRx-3996: 20 mg QD on Days 1 to 4/week valganciclovir: 900 mg QD
    id
    OG002
    title
    Phase 1b Dose Escalation Cohort 3
  4. description
    VRx-3996: 20 mg QD on Days 1 to 4/week valganciclovir: 900 mg QD
    id
    OG003
    title
    Phase 2 RP2D - Capsule
  5. description
    VRx-3996: 20 mg QD on Days 1 to 4/week valganciclovir: 900 mg QD
    id
    OG004
    title
    Phase 2 RP2D - Tablet
param Type
MEAN
population Description
The PK Analysis Set was used for all PK analyses and included all patients in the intent-to-treat population (defined as all enrolled patients) who had at least one postdose measurable PK concentration. The PK Analysis Set will be used for individual plasma concentration listings and summaries of plasma concentrations.
reporting Status
POSTED
time Frame
Phase 1b: Cycle 1 Day 1 and Phase 2: multiple doses through Cycle 2 Day 1
title
Half-life of VRx-3996
type
SECONDARY
unit Of Measure
hours

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice